ArticleDiscover oncology2026
Patterns of relapse and survival outcomes in pediatric ALL from a single center cohort under the CCCG ALL 2015 protocol.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize relapse patterns, identify relapse-related risk factors, and evaluate prognostic determinants of post-relapse outcomes in pediatric acute lymphoblastic leukemia (ALL) patients treated with the Chinese Children's Cancer Group (CCCG)-ALL-2015 protocol.
methodsThis retrospective study included 380 children diagnosed with ALL between 2016 and 2019. We analyzed relapse timing (very early, early, late), relapse sites (bone marrow (BM) vs. extramedullary), early treatment response (morphology and minimal residual disease (MRD)), and post-relapse outcomes. Survival was estimated using Kaplan-Meier methods.
resultsRelapse rate was 11.1% (42/380), predominantly isolated BM (69.0%) and very early timing (47.6%). Relapse varied significantly by risk group (low-risk: 5.9%; intermediate-risk: 10.4%; high-risk: 22.4%; P < 0.001), immunophenotype (B-ALL: 9.8% vs. T-ALL: 23.5%; P = 0.015), Day 19 morphology (M1:9.9% vs. M3:20.0%; P < 0.001), Day 46 morphology (M1:10.5% vs. M3:21.4%; P = 0.025), and Day 46 MRD status (positive:21.4% vs. negative:8.7%; P = 0.002). Fusion gene positivity was significantly associated with earlier relapse timing (P < 0.05). Post-relapse survival differed by relapse timing (very early: 7.2 months; early: 23.2 months; late: 37.8 months; P < 0.001) and initial risk group (low-risk: 38.2 months; high-risk: 18.1 months; P = 0.006).
conclusionsNon-remission on Days 19/46, Day 46 MRD positivity, and high-risk status predict ALL relapse. High-risk patients experience earlier relapses and poorer survival. Fusion gene positivity is associated with earlier relapse timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.